- Home
- QNCX vs BCAB Comparison
QNCX vs BCAB Comparison
Compare QNCX & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNCX | BCAB |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QNCX | BCAB |
|---|---|---|
| Price | $1.33 | $4.87 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 63.5M | 336.4K |
| Earning Date | 04-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.12 |
| 52 Week High | $4.55 | $6.52 |
Technical Indicators
Market Signals| Indicator | QNCX | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 73.92 | 65.21 |
| Support Level | $0.10 | $0.36 |
| Resistance Level | $1.47 | $6.52 |
| Average True Range (ATR) | 0.15 | 0.64 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 86.11 | 42.79 |
Price Performance
Historical ComparisonAbout QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.